Highlights
1 patent
About
Therapy for Glaucoma
NeurOptic's lead product for glaucoma is based on an FDA-approved drug indicated as therapy for neurodegenerative disease. NeurOptic is developing an ophthalmic formulation for glaucoma treatment established on the prolonged residence time of a monoamine oxidase inhibitor on the ocular surface and providing sustained delivery and constant effect of the drug for two months. Preliminary pre-clinical studies showed that the novel topical treatment of NeurOptic's product exerted a significant effect on high levels of intraocular pressure and may prevent neuronal damage in the eye.
Identity
| Name | NeurOptic |
|---|---|
| Slug | neuroptic |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoJGSwbsIDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Apr 2018 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | North District |
| HQ city | Yokne'am Illit |
| HQ address | Ha-Tsmikha Street 1, Yokne'am Illit, Israel |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2C
Tags
pharma-companiesglaucomaeye-diseasesophthalmologypharmaceuticals
Funding
| Total raised | — |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}